This article is for informational purposes only and does not constitute medical advice. Side effect information is drawn from published clinical trial data for branded injectable semaglutide and tirzepatide — compounded formulations available through platforms like MadeMed have not been evaluated through the same clinical trial framework. If you are experiencing side effects, contact your prescribing clinician. If you are experiencing a medical emergency, call 911 immediately.
Most people researching a compounded GLP-1 program spend a lot of time on pricing and legitimacy questions — and not nearly enough time on side effects. That's the wrong order. Side effects are the primary reason people discontinue GLP-1 therapy before it has time to work. Understanding what to expect, what's manageable, and what requires calling your provider will determine whether you stay on the program long enough to see results.
This is the side effect breakdown I wish existed when I started researching these platforms. It pulls from the clinical trial literature for branded semaglutide and tirzepatide — which is the best evidence base available, with the caveat that compounded versions dispensed through platforms like MadeMed haven't been studied through the same clinical trial standard. The active ingredients are the same; the evidence for compounded formulations specifically is not equivalent.
The Most Common Side Effects: All GI, All Dose-Related
The dominant side effect profile for both semaglutide and tirzepatide is gastrointestinal. Nausea, vomiting, diarrhea, and constipation are the most frequently reported across the major clinical trials. In the STEP trials for branded injectable semaglutide, nausea was reported in approximately 44 percent of participants — making it the single most common adverse event. Vomiting occurred in approximately 24 percent, diarrhea in approximately 30 percent, and constipation in approximately 24 percent.
The critical context: these side effects are strongly dose-dependent. They occur most frequently during dose escalation — the period when you're moving from a starter dose to a higher maintenance dose. For most people, GI symptoms diminish significantly as the body adjusts to a stable dose. This is why slow, careful dose escalation is standard clinical practice for GLP-1 therapy, and why discontinuing during the escalation phase — when symptoms are at their worst — means stopping before reaching the therapeutic dose level where outcomes improve.
Tirzepatide and semaglutide share this GI profile. SURMOUNT-5, the head-to-head randomized controlled trial, confirmed that both medications produce similar rates of nausea, vomiting, diarrhea, and constipation. Patients switching from semaglutide to tirzepatide may experience a recurrence of GI symptoms during the transition — clinical guidance recommends restarting tirzepatide at 2.5mg regardless of the prior semaglutide dose to minimize this effect.
Side Effects That Require Contacting Your Provider
Most GI side effects during GLP-1 therapy are uncomfortable but not dangerous, and they're manageable with the strategies in the next section. The following are different — they require contacting your prescribing clinician, not self-managing.
Severe or persistent abdominal pain, particularly pain that radiates to the back, can be a sign of pancreatitis. GLP-1 medications have a known association with pancreatitis risk, though the absolute incidence in clinical trials is low. This is not a symptom to wait out.
A lump or swelling in the neck, difficulty swallowing, or difficulty breathing can indicate a thyroid tumor. Both semaglutide and tirzepatide carry an FDA warning about the risk of thyroid C-cell tumors based on animal studies — though whether this risk translates to humans at clinical doses is not established. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications. This is a clinical screening question your provider at Xpedicare should be addressing during intake.
Persistent vomiting that prevents keeping food or liquid down for an extended period is a clinical issue, not a tolerance problem. Severe dehydration is a real risk in this scenario and requires provider contact, not waiting it out.
Severe allergic reactions — hives, difficulty breathing, swelling of face, lips, tongue, or throat — require emergency evaluation immediately.
Contraindications: Who Shouldn't Use These Medications
GLP-1 medications are not appropriate for everyone. The following are contraindications that should be addressed during your clinical intake with MadeMed's prescribing providers. If your intake form didn't ask about these specifically, raise them directly with your clinician before starting:
Personal or family history of medullary thyroid carcinoma. Personal or family history of Multiple Endocrine Neoplasia syndrome type 2. History of pancreatitis. Severe gastrointestinal disease. Pregnancy — GLP-1 medications are not approved for use during pregnancy, and discontinuation is recommended at least two months before a planned pregnancy based on current clinical guidance. Diabetic retinopathy — rapid glucose reduction has been associated with worsening of diabetic retinopathy in some patients; this requires monitoring if applicable.
How to Manage Common GI Side Effects
These strategies are consistent with standard clinical practice for GLP-1 therapy and are generally recommended by providers managing patients on these medications. They are not a substitute for contacting your provider if symptoms are severe.
Eat smaller portions at each meal. GLP-1 medications slow gastric emptying — large meals are harder to process and amplify nausea. Reduce portion sizes before reducing meal frequency.
Avoid high-fat, greasy, or highly spiced foods during the escalation phase. These food categories exacerbate nausea on GLP-1 therapy specifically.
Eat slowly and stop before feeling full. The satiety signal on GLP-1s arrives more gradually than it does without medication — eating to the point of fullness before the signal arrives leads to nausea and discomfort.
Stay upright after eating. Lying down immediately after meals worsens nausea on GLP-1 therapy.
Hydrate consistently. Constipation is a common side effect, and adequate water intake is the first-line management strategy.
Do not escalate your dose to manage symptoms. If side effects are not improving at a given dose, the clinical approach is to hold the current dose longer or step back to a lower dose — not push through to a higher one. Contact your prescribing clinician for dose management guidance.
A Note Specific to Oral Sublingual Formats
MadeMed offers both injectable and oral sublingual (under-the-tongue) formats for semaglutide and tirzepatide. The side effect profile described above is based on injectable branded formulations studied in clinical trials. For compounded oral sublingual versions, the pharmacokinetics — how much of the active ingredient is absorbed and at what rate — are not established through the same clinical evidence base. This has two implications for side effects specifically: the onset and severity of GI effects may differ from what injectable trial data predicts, and if absorption is meaningfully lower than injectable delivery, therapeutic dose and side effect exposure may both be affected. Discuss delivery format and what to expect at your specific dose with your prescribing clinician.
What This Means for Your MadeMed Decision
The side effect profile for GLP-1 medications is real, it's primarily GI, and it's front-loaded during dose escalation. For most people who stay on the program through escalation, symptoms become manageable. The people who discontinue and conclude the medication doesn't work for them are frequently the people who stopped during the hardest stretch — before reaching a therapeutic maintenance dose.
Going in with accurate expectations is the single most useful thing you can do to improve your odds of getting through escalation. That means knowing nausea is likely for the first several weeks, that it typically improves, that there are management strategies that help, and that your prescribing clinician should be an active resource — not just an intake form you filled out once.
For the full platform overview including pricing and enrollment, see the MadeMed review. For how MadeMed compares to MEDVi on program structure, see the MadeMed vs. MEDVi comparison.
Frequently Asked Questions
What are the most common side effects of semaglutide and tirzepatide?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These occur most frequently during dose escalation and typically decrease as the body adjusts. In the STEP trials for branded injectable semaglutide, nausea was reported in approximately 44 percent of participants. Side effects for compounded formulations have not been studied in the same clinical trial framework.
Are side effects worse with tirzepatide than semaglutide?
Both medications share a similar gastrointestinal side effect profile. Patients switching from semaglutide to tirzepatide may experience enhanced GI effects during the transition period. Clinical guidance recommends starting tirzepatide at 2.5mg regardless of prior semaglutide dose to minimize this risk.
What side effects require contacting a provider immediately?
Contact your provider immediately if you experience: severe or persistent abdominal pain (possible pancreatitis), symptoms of a thyroid tumor including a lump in the neck, difficulty swallowing or breathing, or persistent vomiting preventing you from keeping food or liquid down. These are serious events requiring clinical evaluation, not self-management.
How do you reduce nausea on GLP-1 medications?
Clinical practice recommendations include eating smaller meals, avoiding high-fat or spicy foods, eating slowly, and not lying down immediately after eating. Most providers also recommend slow dose escalation — starting at the lowest dose and only increasing when the current dose is well tolerated. Do not increase your dose to manage side effects; contact your prescribing clinician instead.
Leave a Reply
You must be logged in to post a comment.